Objective of the study was to determine whether L.rhamnosus strains (573L/1; 573L/2; 573L/3) enclosed in the preparation Lakcid L®, have an influence on acute diarrhea in children from 2 m. to 6 y. old. Randomized, double-blind, placebo-controlled trial was performed. Primary outcome measure was the diarrhea duration. Secondary outcome measures were: weight gain, no. of stools in consecutive days, duration of parenteral rehydration, diarrhea lasting over 7 days and GI tract colonization by administered strains. 93 patients were enrolled to the study. Children were treated according to ESPGHAN recommendation and additionaly , they received either 1.2 1010 CFU mixture of L. rhamnosus strains or placebo twice daily for 5 consecutive days. Results: 87/93 (93,5%) patients were analyzed. 46/87 (52,9%) children were in probiotic group and 41/87 (47,1%) were in placebo group. 39/87 (44,8%) had rotaviral infection (22 recived Lakcid L, 17 recived placebo. Mean duration of diarrhea in the treated group: 83.6 ± 55.6 h; in placebo group: 96 ± 71.5 h (p=0,36). In rotavirus infection: 77.5 ± 35.4 h vs 115 ± 66.9 h (p=0,03), respectively. Duration of parenteral rehydration 14.9 ± 13.7 h vs 37.6 ± 32.9 h; (p=0,006). The applied probiotic strains were detected in stool samples of 37/46 (80.4%) children in 5 days and in 19/46 (41.3%) samples in 14 days after initiating the treatment. Conclusio ; ns: Lakcid L administered orally in dose 1,2x1010CFU twice daily for 5 consecutive days has no influence on diarrhea of any etiology but shortens the duration of rotaviral diarrhea in children which is probably related to succsessful gut colonization.
26 cze 2023
21 lis 2012
687
150
http://dl.cm-uj.krakow.pl:8080/publication/1244
Nazwa wydania | Data |
---|---|
ZB-102656 | 26 cze 2023 |
Szymański, Henryk
Szymański,H. (oprac ).
Kowalska-Duplaga, Kinga
Brzychczy-Włoch, Monika
Chmielarczyk, Agnieszka
Ziemniak, Witold
Ciszek-Lenda, Marta.
Jagielski, Paweł